• Business
    • Global report
  • Regulatory
  • Pharmacovigilance
  • Manufacturing
    • GMP
    • Quality assurance
  • R&D
    • API
    • Excipients
    • Trials
    • Drug Delivery
    • Technology
  • Companies
    • Contract manufacturing
    • Equipment
    • Outsourcing
    • Packaging
    • Supply chain
    • Technology Transfer
  • EIPG Newsletter
    • Technology & Production
    • Regulatory
    • Politics & Business
    • Focus on EU’s Countries
    • News from EIPG
Search
  • Who we are
  • How to use and read
Pharma World
  • Business
    • Global report
  • Regulatory
  • Pharmacovigilance
  • Manufacturing
    • GMP
    • Quality assurance
  • R&D
    • API
    • Excipients
    • Trials
    • Drug Delivery
    • Technology
  • Companies
    • Contract manufacturing
    • Equipment
    • Outsourcing
    • Packaging
    • Supply chain
    • Technology Transfer
  • EIPG Newsletter
    • Technology & Production
    • Regulatory
    • Politics & Business
    • Focus on EU’s Countries
    • News from EIPG
Home Authors Posts by Manuele Cantù

Manuele Cantù

1 POSTS 0 COMMENTS

HAZEL® GATEWAY GW-MB1: simplify the validation of recovery times in...

Manuele Cantù - 29 March 2021
0

Recent Posts

  • HAZEL® GATEWAY GW-MB1: simplify the validation of recovery times in airlocks
  • EIPG: Upcoming events and a call for consultation
  • The economic footprint of the biotechnology industry in Europe: Focus in Pharma
  • Comments to the public consultation on the new HERA agency
  • Structured dialogue with the EU Commission to prevent shortages

Latest Updates

  • 2018/04 - December

    2018/04 – December

  • 2018/03 – November

  • 2018/02 – June

  • 2018/01 – May

Subscribe to our newsletter

Translate

NCF – Notiziario Chimico Farmaceutico

RSS NCF

  • 61° Simposio AFI: le Sessioni Scientifiche di giovedì 9 giugno
  • L’evoluzione delle norme sul tema della Computer System Validation
  • Terapia cellulare CAR-T, la CE autorizza lisocabtagene maraleucel
  • EuropaBio, raccomandazioni per lo sviluppo del settore biotech e un nuovo forum per le PMI
  • Il settore delle biotecnologie alla luce del rapporto annuale Assobiotec-Federchimica ed ENEA 
© 2020 Tecniche Nuove Spa • Tutti i diritti riservati. Sede legale: Via Eritrea 21 - 20157 Milano. Capitale sociale: 5.000.000 euro interamente versati. Codice fiscale, Partita Iva e Iscrizione al Registro delle Imprese di Milano: 00753480151